A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients

被引：1

作者：

Oh, Mi Jin ^{[1
]}

Shin, Dong-Yeop ^{[1
,2
,3
]}

Koh, Youngil ^{[1
,2
,3
]}

Hong, Junshik ^{[1
,2
,3
]}

Kim, Inho ^{[1
]}

Yoon, Sung-Soo ^{[1
,2
,3
]}

Byun, Ja Min ^{[1
,2
,3
]}

机构：

[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea

[2] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Ctr Med Innovat, Biomed Res Inst, Seoul, South Korea

来源：

IN VIVO | 2021年 / 35卷 / 01期

关键词：

Acute myeloid leukemia; intermediate risk; allogeneic hematopoietic stem cell transplantation; VERSUS-HOST-DISEASE; DIAGNOSIS;

D O I：

10.21873/invivo.12299

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally recommended as consolidation after first complete remission (CR1). In real-world, alloSCT might not be readily available, but there is paucity of data on the optimal timing of alloSCT for these patients. Patients and Methods: In this pilot study, we compared the outcomes of 13 patients undergoing alloSCT in CR1 with 13 patients undergoing alloSCT after relapse (non-CR1) to examine whether upfront alloSCT yields a better prognosis. Results: There were no differences between the two groups with regards to relapse-free survival (p=0.507) and overall survival (p=0.798). There were more chronic graft-versus-host-disease (GVHD) in the CR1 group compared to the non-CR group (p=0.001), but no difference in acute GVHD. Conclusion: The outcome of alloSCT after relapse is not inferior to that of alloSCT in CR1, supporting the role of alloSCT after relapse in the setting of limited donors and resources.

引用

页码：617 / 622

页数：6

共 13 条

[1] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].

Filipovich, AH ;

Weisdorf, D ;

Pavletic, S ;

Socie, G ;

Wingard, JR ;

Lee, SJ ;

Martin, P ;

Chien, J ;

Przepiorka, D ;

Couriel, D ;

Cowen, EW ;

Dinndorf, P ;

Farrell, A ;

Hartzman, R ;

Henslee-Downey, J ;

Jacobsohn, D ;

McDonald, G ;

Mittleman, B ;

Rizzo, JD ;

Robinson, M ;

Schubert, M ;

Schultz, K ;

Shulman, H ;

Turner, M ;

Vogelsang, G ;

Flowers, MED .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956

[2] Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission [J].

Burnett, Alan K. ;

Goldstone, Anthony ;

Hills, Robert K. ;

Milligan, Donald ;

Prentice, Archie ;

Yin, John ;

Wheatley, Keith ;

Hunter, Ann ;

Russell, Nigel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1293-1301

[3] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[4] Acute myeloid leukemia: 2019 update on risk-stratification and management [J].

Estey, Elihu H. .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (10) :1267-1291

[5] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].

Filipovich, AH ;

Weisdorf, D ;

Pavletic, S ;

Socie, G ;

Wingard, JR ;

Lee, SJ ;

Martin, P ;

Chien, J ;

Przepiorka, D ;

Couriel, D ;

Cowen, EW ;

Dinndorf, P ;

Farrell, A ;

Hartzman, R ;

Henslee-Downey, J ;

Jacobsohn, D ;

McDonald, G ;

Mittleman, B ;

Rizzo, JD ;

Robinson, M ;

Schubert, M ;

Schultz, K ;

Shulman, H ;

Turner, M ;

Vogelsang, G ;

Flowers, MED .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956

[6] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].

GLUCKSBERG, H ;

STORB, R ;

FEFER, A ;

BUCKNER, CD ;

NEIMAN, PE ;

CLIFT, RA ;

LERNER, KG ;

THOMAS, ED .

TRANSPLANTATION, 1974, 18 (04) :295-304

[7] Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up [J].

Heuser, M. ;

Ofran, Y. ;

Boissel, N. ;

Mauri, S. Brunet ;

Craddock, C. ;

Janssen, J. ;

Wierzbowska, A. ;

Buske, C. .

ANNALS OF ONCOLOGY, 2020, 31 (06) :697-712

[8] Prognostic effect of allogeneic hematopoietic stem cell transplantation on first and non-first complete remission in acute myeloid leukemia [J].

Hu, Ning ;

Cheng, Zhiheng ;

Pang, Yifan ;

Zhao, Hongmian ;

Ding, Hui ;

Chen, Li ;

Li, Qianyu ;

Han, Yu ;

Qin, Tong ;

Dai, Yifeng ;

Zhang, Yijie ;

Shi, Jinlong ;

Wu, Depei ;

Fu, Lin .

ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)

[9] Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials [J].

Koreth, John ;

Schlenk, Richard ;

Kopecky, Kenneth J. ;

Honda, Sumihisa ;

Sierra, Jorge ;

Djulbegovic, Benjamin J. ;

Wadleigh, Martha ;

DeAngelo, Daniel J. ;

Stone, Richard M. ;

Sakamaki, Hisashi ;

Appelbaum, Frederick R. ;

Doehner, Hartmut ;

Antin, Joseph H. ;

Soiffer, Robert J. ;

Cutler, Corey .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (22) :2349-2361

[10]

National Comprehensive Cancer Network, 2020, NATIONAL COMPREHENSI

← 1 2 →